Aizon, a San Francisco-based Artificial Intelligence (AI) software-as-a-service (SaaS) company focusing on enhancing pharmaceutical manufacturing, has successfully secured $20 million in Series C funding. The funding round was led by NewVale Capital, with participation from existing investors Atlantic Bridge, Crosslink Capital, and Uncork Capital.

The primary aim of this funding is to accelerate Aizon’s development pipeline and bolster its ability to cater to its clientele effectively. With CEO Pep Gubau at the helm, Aizon utilizes advanced predictive analytics, AI, and smart factory technologies to provide a user-friendly GMP AI platform for pharmaceutical manufacturers.

This recent investment reflects the growing recognition of Aizon’s role in AI-enhanced pharmaceutical manufacturing. It further emphasizes the company’s commitment to maintaining a leading position in the industry by delivering innovative solutions that prioritize quality, compliance, and efficiency.

Aizon’s technology enables clients to access insights, make informed decisions, predict deviations, and optimize manufacturing processes. The company adheres to stringent quality and compliance standards, following GAMP5 for GMP processes to ensure data integrity and regulatory adherence.

Pep Gubau, CEO and co-founder of Aizon, views this investment as instrumental in the company’s growth trajectory, stating, “This investment is pivotal to the future growth of our company as it validates the success of our platform and enables us to better execute on our strategic roadmap.”

Todd Holmes, managing partner at NewVale Capital, expressed confidence in Aizon’s potential to make a significant impact in the pharmaceutical manufacturing landscape. He remarked, “Aizon’s AI-driven solutions are poised to transform the industry, and we are excited to play a role in this next chapter of growth.”

Aizon’s focus on advancing pharmaceutical manufacturing through AI-driven solutions, coupled with strategic investments, positions the company as a key player in driving technological advancements and improving outcomes in the life sciences sector.

For more information about Aizon and its solutions, visit aizon.ai